Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
This article was originally published in The Tan Sheet
Executive Summary
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.
You may also be interested in...
Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
US federal court judge says Mucinex marketer Reckitt Benckiser is not responsible for OTC private label competitor Aurobindo’s attorney fees because its patent infringement complaint was not “exceptional” and its argument had merit. The decision could bolster drug firms' confidence in defending their patents.
Decision Against Attorney Fees In Mucinex Patent Claim Could Resonate
US federal court judge says Mucinex marketer Reckitt Benckiser is not responsible for OTC private label competitor Aurobindo’s attorney fees because its patent infringement complaint was not “exceptional” and its argument had merit. The decision could bolster drug firms' confidence in defending their patents.
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo launches store brand Mucinex D, containing guaifenesin and PSE, manufactured by Allergan, but also suspends marketing its own guaifenesin product due to problems with an excipient used in the formula.